Skip to main content
Hengrui Pharma logo

Hengrui Pharma — Investor Relations & Filings

Ticker · 600276 ISIN · CNE0000014W7 LEI · 2549003BT1XS3SE3E448 HKEX Manufacturing
Open in API
Filings indexed 2,702 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country CN China
Listing HKEX 600276

About Hengrui Pharma

https://www.hrs.com

Hengrui Pharma is an innovative, global pharmaceutical company focused on the research, development, manufacturing, and commercialization of medicines. The company specializes in therapies for oncology, surgical applications, and interventional imaging. With a strong commitment to R&D, Hengrui has developed and commercialized numerous new molecular entities and is expanding its portfolio to address unmet medical needs in international markets. Its core activities revolve around creating high-quality and accessible treatments, particularly in the field of cancer therapy.

Recent filings

Filing Released Lang Actions
恒瑞医药差异化分红事项法律意见书
Regulatory Filings Classification · 96% confidence The document is a legal opinion (“法律意见书”) prepared by an outside law firm for Jiangsu Hengrui Pharmaceuticals regarding the legal compliance of a differentiated dividend distribution plan. It contains no financial statements or earnings, no management discussion, nor is it an investor presentation or dividend notice per se. Instead, it is a compliance/legal opinion letter intended for submission to the stock exchange. This falls under the fallback category of general regulatory/compliance filings. Therefore, it should be classified as Regulatory Filings (RNS).
2026-05-20 Chinese
恒瑞医药关于获得药品注册批准的公告
Regulatory Filings Classification · 40% confidence The document is an official announcement by the company’s board disclosing that its subsidiary received drug registration approval from the National Medical Products Administration. It is an operational/regulatory news release regarding product approval rather than a financial report, management change, capital structure update, or any specialized category. It does not contain financial statements or specific regulatory form references, so under the taxonomy it falls into the general “Regulatory Filings” fallback category (RNS).
2026-05-19 Chinese
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement by Jiangsu Hengrui Medicine Co., Ltd. (stock code 600276) regarding its subsidiary receiving a clinical trial approval notice from the National Medical Products Administration. It provides details on the drug, the approval process, and risk reminders. This is not a financial report, earnings release, management change notice, or AGM material. It is a regulatory disclosure of a non-financial matter (drug approval) required under listing rules. Hence, it falls under general Regulatory Filings (RNS).
2026-05-14 Chinese
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings
2026-05-08 Chinese
恒瑞医药关于获得药物临床试验批准通知书的公告
Regulatory Filings
2026-05-08 Chinese
恒瑞医药关于回购公司A股股份的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a progress announcement regarding the company's share repurchase (buyback) plan. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document is relatively short (1337 characters) and focuses on the update of the share buyback activity rather than presenting a full financial report or analysis. It matches the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares.
2026-05-07 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.